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SurvivalAbstract Background: In recent years, new treatment options have become available for
pancreatic ductal adenocarcinoma (PDAC) including 5-fluorouracil, leucovorin, irinotecan
and oxaliplatin. The impact hereof has not been assessed in nationwide cohort studies. This
population-based study aimed to investigate nationwide trends in incidence, treatment and
survival of PDAC.
Materials and methods: Patients with PDAC (1997e2016) were included from the Netherlands
Cancer Registry. Results were categorised by treatment and by period of diagnosis (1997
e2000, 2001e2004, 2005e2008, 2009e2012 and 2013e2016). KaplaneMeier survival analysis
was used to calculate overall survival.
Results: In a national cohort of 36,453 patients with PDAC, the incidence increased from 12.1
(1997e2000) to 15.3 (2013e2016) per 100,000 (p < 0.001), whereas median overall survival
increased from 3.1 to 3.8 months (p < 0.001). Over time, the resection rate doubled (8.3%
e16.6%, p-trend<0.001), more patients received adjuvant chemotherapy (3.0%e56.2%, p-
trend<0.001) and 3-year overall survival following resection increased (16.9%e25.4%,
p < 0.001). Over time, the proportion of patients with metastatic disease who received palli-
ative chemotherapy increased from 5.3% to 16.1% (p-trend<0.001), whereas 1-year survival
improved from 13.3% to 21.2% (p < 0.001). The proportion of patients who only received sup-
portive care decreased from 84% to 61% (p-trend<0.001).
Conclusion: The incidence of PDAC increased in the past two decades. Resection rates and use
of adjuvant or palliative chemotherapy increased with improved survival in these patients. In
all patients with PDAC, however, the survival benefit of 3 weeks is negligible because the ma-
jority of patients only received supportive care.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a
devastating disease with a poor survival. Reported 5-
year relative survival rates range around 8.5%, and in
2018 alone, 430,000 patients died from PDAC
worldwide [1]. In the last two decades, studies showed
an improved survival in patients with PDAC based
on new oncological treatments. In 2007, a randomised
controlled trial demonstrated that the use of adjuvant
gemcitabine-improved survival in patients after
resection [2]. Randomised trials also demonstrated
that the use of FOLFIRINOX (5-fluorouracil, leu-
covorin, irinotecan and oxaliplatin), and gemcitabine
plus nab-paclitaxel improved survival in patients with
metastatic PDAC, as compared with gemcitabine
alone [3e5]. In addition, prospective cohort studies
and a systematic review described that FOLFIR-
INOX improved survival in patients with locally
advanced PDAC, though randomised studies are not
yet available [6e9].
It is currently unclear what the impact of these im-
provements in the treatment of PDAC has been on a
nationwide scale [10]. It is known that the strict eligi-
bility criteria in randomised trials hamper extrapolation
to the general population. Global trends of PDAC have
recently been reviewed, but the most recent nationwide
evaluation from Europe dates over a decade ago (i.e.
2008) [11e13].In 2012, the Dutch Pancreatic Cancer Group was
formed with the aim to improve survival of PDAC.
Since then, the centralisation and standardisation of
PDAC care in the Netherlands has continued, and the
implementation of new chemotherapy regimens has
been supported. We were interested whether these de-
velopments have changed the survival of patients with
PDAC on a population-based scale in the Netherlands.
The objective of this study, therefore, is to evaluate
trends in incidence, treatment and survival for patients
with all stages of PDAC in the Netherlands between
1997 and 2016.
2. Materials and methods
2.1. Study design
All patients with primary PDAC diagnosed from 1997
to 2016 were included from the Netherlands Cancer
Registry (NCR), a population-based database that
covers all Dutch hospitals (i.e. a population of 17.3
million). Patients with a newly diagnosed malignancy
are identified by two-step signalling consisting of (1)
automatic notifications of the national pathological
archive and the National Registry of Hospital Discharge
Diagnoses and (2) verification of notifications in medical
files in hospitals. Patient, tumour and treatment char-
acteristics are routinely collected from medical records
by trained NCR administrators. This study was
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[14]. The scientific committee of the Dutch Pancreatic
Cancer Group approved the study protocol.
2.2. Study population
Patients with primary PDAC were included. This diag-
nosis was based on the International Classification of
Disease-Oncology (ICD-O-3) morphology codes accord-
ing to the WHO classification (Supplementary Material)
[15]. Patients aged younger than 18 years at diagnosis or
patients diagnosed during autopsy were excluded.
2.3. Data collection
Socioeconomic status (SES) was based on social depri-
vation scores per 4-digit postal code (reference data
from The Netherlands Institute of Social Research) and
categorised into three SES groups (high: 1st-3rd, inter-
mediate 4th-7th, low: 8th-10th deciles). The time of
diagnosis was divided into five periods: 1997e2000,
2001e2004, 2005e2008, 2009e2012 and 2013e2016 to
facilitate analyses. Primary tumour location was classi-
fied as pancreatic head, body, tail or other/non-specified
(C25.3, C25.5e9), according to the ICD-O-3 codes.
Tumour stage was based on the pathological tumour-
node-metastasis (TNM) classification at the time of
registration (revised 4th edition of IUCC TNM staging
during 1997e1998, 5th edition during 1999e2002, 6th
edition during 2003e2009, 7th edition during
2010e2016), supplemented with the clinical TNM clas-
sification in case of non-resected tumours or neo-
adjuvant therapy [16e19]. A one-digit summary stage
(Extent of Disease) was recorded in patients without
pathological confirmation of cancer [20]. Based on the
tumour stage at primary diagnosis and the primary
subsequent treatment, patients with PDAC were divided
into four groups: (1) patients with localised disease who
underwent resection with or without (neo)adjuvant
chemo (radio)therapy; (2) patients with localised disease
who received chemo (radio)therapy without resection
(patients with locally advanced pancreatic cancer and
patients unfit for surgery); (3) patients with metastatic
disease at diagnosis who received chemotherapy; (4)
patients who received supportive care only (and did not
receive any tumour directed therapy). Patients treated
with chemotherapy but without the possibility to
distinguish metastatic or localised diseased (n Z 43)
were excluded. Time to treatment analyses could not be
performed because the diagnosis is based on pathology
which was often the date of surgery. Furthermore, date
of resection was only available since 2015 and start of
chemotherapy since 2011. Survival was defined as the
time between date of diagnosis and date of death or
censored at last follow-up date and was obtained bylinkage of the NCR with the Municipal Personal Re-
cords Database (updated in February 2019).
2.4. Statistical analysis
The incidence of PDAC was described in new cases per
100.000 persons per year stratified by sex, together with
the estimated annual percent of change (EAPC). To
compare results with old and new literature, the inci-
dence rates were age-standardised to both the European
standard population from 1976 (ESP) and the revised
ESP from 2013 (RESP) [21,22]. The age-standardised
incidence is the incidence that would be observed if the
study population had the age structure of the standard
population and is essential to compare rates over time or
between geographical regions. Imputation was not per-
formed, and missing data were described in the baseline
characteristics. Trends over time in treatment were
analysed with the Chi-square test for trend. Median
overall survival, 3-month survival and 1-, 3- and 5-year
survival were calculated using the KaplaneMeier
method and compared using the log rank test. Ana-
lyses were based on type of treatment and stratified by
period. To demonstrate whether changes in resection
and chemotherapy rate were associated with differences
in overall survival over time, multivariable Cox regres-
sion models, adjusted for potential confounders, were
performed without and with these treatment variables.
Potential confounders were sex, age, SES, primary
tumour location and tumour stage. Results were pre-
sented as hazard ratios (HRs) with 95% confidence in-
tervals (CIs). All p-values were based on a 2-sided test,
and p-values of <0.05 were considered statistically sig-
nificant. Data were analysed using IBM SPSS Statistics
for Windows, version 25 (IBM Corp., Armong, NY,
USA), SAS version 9.4 (SAS Institute Inc., Cary, NC,
USA) and R version 3.4.3 (cran.r-project.org).
3. Results
From 1997 to 2016, 36,453 patients were diagnosed with
PDAC. The incidence increased from 12.1 to 15.3 per
100,000 persons from 1997 to 2016 (RESP-based,
EAPC 1.5%, p < 0.001, Fig. 1A). The incidence was
higher in males and increased significantly for both sexes
from 1997 to 2016 (RESP-based, EAPC 1.5%, p < 0.001
and EAPC 1.6%, p < 0.001, respectively). The ESP-
based incidence increased similarly with an EAPC of
1.5% for the overall group (Fig. 1B). Median age at
diagnosis was 71 years (Table 1). The incidence was
highest in patients aged 60e74 year compared with pa-
tients aged <60 year or 75 year, but increased signifi-
cantly in all age categories (RESP based, EAPC 1.95
p < 0.001, EAPC 0.87 p Z 0.01 and EAPC p < 0.001,
respectively, Fig. 2A).
Fig. 1. Age-standardised incidence rates of patient with pancreatic ductal adenocarcinoma in the Netherlands stratified by sex (1997e2016).
Fig. 1A. Age-standardised incidence rates based on the Revised European Standard Population; Fig. 1B. Age-standardised incidence rates
based on the European Standard Population.
A.E.J. Latenstein et al. / European Journal of Cancer 125 (2020) 83e93863.1. All stages pancreatic cancer
Pathological confirmation increased over the years from
58.4% in 1997e2000 to 71.9% in 2013e2016 (p-
trend<0.001). Metastatic disease at diagnosis was pre-
sent in 19,119 patients (52.4%) and increased from
45.2% in 1997e2000 to 57.0% in 2013e2016 (p-
trend<0.001). More patients were treated with (neo)
adjuvant or palliative chemotherapy (Table 2). Medianoverall survival was 3.5 months (95%CI 3.5e3.6) for the
entire cohort and increased from 3.1 months in
1997e2000 to 3.8 months in 2013e2016 (p < 0.001,
Table 1). Survival at 3 months after diagnosis increased
from 50.9% (95%CI 49.6e52.2) to 56.5% (95%CI
55.5e57.5) (p < 0.001, Fig. 3D) and 1-year survival
from 13.4% (95%CI 12.5e14.3) to 21.0% (95%CI
20.1e21.8, p < 0.001). The association between time
period of diagnosis and overall survival was significant
Table 1
Patient, tumour and treatment characteristics of 36,453 patients diagnosed with pancreatic ductal adenocarcinoma between 1997 and 2016 in the
Netherlands.
Characteristics All patients
(n Z 36,453)
Patients with
localised disease
who underwent
resection
(n Z 4387)
Patients with
localised disease
who received
chemo (radio)
therapy
(n Z 1604)
Patients with
distant
metastases who
received
chemotherapy
(n Z 4074)
Patients who
only received
supportive care
(n Z 26,388)
Male 18,161 (59.8%) 2348 (53.5%) 873 (54,4%) 2288 (56,2%) 12,652 (47.9%)
Age, median (IQR) 71.0 (62.0e78.0) 66.0 (59.0e72.0) 64.0 (56.0e70.0) 63.0 (56.0e69.0) 74.0 (65.0e80.0)
<60 years 6658 (18.3%) 1184 (27.0%) 556 (34.7%) 1491 (36.6%) 3427 (13.0%)
60e74 years 16,300 (44.7%) 2488 (56.7%) 877 (54.7%) 2267 (55.6%) 10,668 (40.4%)
75 years 13,495 (37.0%) 715 (16.3%) 171 (10.7%) 316 (7.8%) 12,293 (46.6%)
SES
Low 10,862 (29.8%) 1389 (31.7%) 511 (31.9%) 1323 (32.5%) 7639 (28.9%)
Medium 14,610 (40.1%) 1775 (405%) 626 (39.0%) 1649 (40.5%) 10,560 (40.0%)
High 10,981 (30.1%) 1223 (27.9%) 467 (29.1%) 1102 (27.0%) 8189 (31.0%)
Primary tumour location
Head of pancreas 23,129 (63.4%) 3559 (81.1%) 1097 (6.,4%) 1810 (44.4%) 16,663 (63.1%)
Body of pancreas 3589 (9.8%) 166 (3.8%) 258 (16.1%) 666 (16.3%) 2499 (9.5%)
Tail of pancreas 4682 (12.8%) 319 (7.3%) 68 (4.2%) 956 (23.5%) 3339 (12.7%)
Other/non-specified (C25.3, C25.5e9) 5053 (13.9%) 343 (7.8%) 181 (11.3%) 642 (15.8%) 3887 (14.7%)
Tumour stagea
Local disease/within pancreas 3915 (10.7%) 594 (13.5%) 125 (7.8%) e 3196 (12.1%)
Extended disease/growth outside pancreas 10,776 (29.6%) 3579 (81.6%) 1451 (90.5%) e 5746 (21.8%)
Metastatic disease 19,119 (52.4%) 185 (4.2%) e 4074 (100%) 14,860 (56.3%)
Unknown 2643 (7.3%) 29 (0.7%) 28 (1.7%) e 2586 (9.8%)
Overall survival in months, median (95% CI) 3.5 (3.5e3.6) 16.9 (16.4e17.4) 10.5 (10.1e11.0) 5.8 (5.7e6.0) 2.3 (2.3e2.3)
Patient treated with chemo (radio)therapy 21.9 (20.8e23.1)
Patients not treated with chemo (radio)therapy 13.4 (12.8e14.1)
IQR, interquartile range; SES, socioeconomic status; CI, confidence interval; TNM, tumour-node-metastasis.
a Tumour stage was based on the pathological TNM classification at the time of registration, supplemented with the clinical TNM or a
summary stage (no microscopic verification) in case of non-resected tumours or neoadjuvant therapy.
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resection and chemotherapy treatment to the Cox
model, this association disappeared for all periods
except for 2001e2004 (Table 3).3.2. Patients with localised disease who underwent
resection
Resection was performed in 4387 patients (12.0%), and
this percentage doubled from 8.3% in 1997e2000 to
16.6% in 2013e2016 (p-trend<0.001). This increase
applied to all age groups (<60 years from 15.2% to
23.8%, 60e74 years from 10.7% to 19.4% and 75 years
from 2.0% to 9.6%). The use of adjuvant chemotherapy
increased from 3.0% in 1997e2000 to 21.1% in
2005e2008 and 56.2% in 2013e2016 (p < 0.001, Table
2). In 2013e2016, 8.5% of patients who underwent
resection received neoadjuvant chemotherapy. The use
of (mainly adjuvant) radiotherapy remained negligible
over the years (3.5% of patients).
In all patients who underwent resection, median
overall survival was 16.9 months (95% CI 16.4e17.4,
Table 1 and Fig. 3A). Median overall survival was better
with (neo)adjuvant chemotherapy (21.9 months, 95% CI
20.8e23.1) than without (13.4 months, 95% CI
12.8e14.1, p < 0.001, Supplemental Fig. 1A and B). Inall patients after resection, 1-year survival increased
significantly from 56.1% (95%CI 51.8e60.8) in
1997e2000 to 68.7% (95%CI 66.5e71.1) in 2013e2016
and 5-year survival from 9.1% (95%CI 6.8e12.2) to
16.5% (95%CI 14.3e18.9), respectively.
3.3. Patients with localised disease who received
chemo(radio)therapy without resection
Of all patients with PDAC, 1604 patients (4.4%) had
localised disease and received chemo (radio)therapy
without resection (Table 2). This proportion of patients
increased from 2.1% in 1997e2000 to 5.8% in
2013e2016 (p-trend < 0.001). Pathological confirmation
was present in 1363 of these patients (85.0%). The use of
radiotherapy decreased from 39.5% to 17.7% (p-trend <
0.001). Median overall survival was 11 months (95% CI
10e11, Table 1). Three-month and 1-year and 3-year
survival were relatively constant over time (Fig. 3B).
3.4. Patient with metastatic disease who received
chemotherapy
In total, 4074 patients (11.2% of patients with all stages
of PDAC, 21.3% of patients with metastatic disease)
received chemotherapy for distant metastases (Table 2).
Fig. 2. Age-standardised incidence rates of patient with pancreatic ductal adenocarcinoma in the Netherlands stratified by age (1997e2016).
Fig. 2A Age-standardised incidence rates based on the Revised European Standard Population. Fig. 2B. Age-standardised incidence rates
based on the European Standard Population.
Table 2
Trends in treatment.
Patients 1997e2016
n Z 36,453
1997e2000
n Z 5572
2001e2004
n Z 5858
2005e2008
n Z 7179
2009e2012
n Z 8470
2013e2016
n Z 9374
p-value
(trend over periods)
Patients with localised disease who
underwent resection
4387 (12.0%) 465 (8.3%) 485 (8.3%) 730 (10.2%) 1153 (13.6%) 1554 (16.6%) <0.001
Neoadjuvant chemotherapy 168 (3.8%) 1 (0.2%) 4 (0.8%) 7 (1.0%) 24 (2.1%) 132 (8.5%) <0.001
Adjuvant chemotherapy 1646 (37.5%) 14 (3.0%) 33 (6.8%) 154 (21.1%) 571 (49.5%) 874 (56.2%) <0.001
Patients with localised disease who
received chemo(radio)therapy
1604 (4.4%) 119 (2.1%) 149 (2.5%) 321 (4.5%) 463 (5.5%) 552 (5.8%) <0.001
Patients with metastatic disease
who received chemotherapy
4074 (11.2%) 294 (5.3%) 420 (7.2%) 660 (9.2%) 1188 (14.0%) 1512 (16.1%) <0.001
Patients who only received
supportive care
26,388 (72.4%) 4694 (84.2%) 4804 (82.0%) 5468 (76.2%) 5666 (66.9%) 5756 (61.4%) <0.001
A.E.J. Latenstein et al. / European Journal of Cancer 125 (2020) 83e9388In 3724 treated patients (91.4%), the tumour was path-
ologically confirmed. The proportion of patients who
received chemotherapy for distant metastases increased
from 5.3% in 1997e2000 to 16.1% of all patients with
PDAC in 2013e2016 (p-trend < 0.001) and from 11.7%to 28.3% of patients with metastatic disease (p-trend <
0.001), respectively. The use of radiotherapy decreased
from 7.8% to 1.1%, p-trend < 0.001. Median overall
survival was 5.9 months (95% CI 5.7e6.0, Table 1 and
Fig. 3C) and the 1-year survival increased from 13.3%
Fig. 3. KaplaneMeier curve and survival at 3 months, 1, 3, 5 years among patients with pancreatic ductal adenocarcinoma per period of
diagnosis (1997e2016). Fig. 3A. Survival of patients with localised disease who underwent tumour resection; Fig. 3B. Survival of patients
with localised disease who received chemo (radio)therapy without resection; Fig. 3C. Survival of patients with synchronous distant
metastases who received chemotherapy; Fig. 3D. Survival of all patient. CI, confidence interval.
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19.2e23.3) in 2013e2016 (p < 0.001).
3.5. Patients who received supportive care only
The majority of patients with PDAC (72.4%) received
supportive care only. This percentage decreased signifi-
cantly (84% in 1997e2000 to 61% in 2013e2016, Table
2, p-trend<0.001). Median overall survival was 2.3
months (70 days, 95%CI 2.3e2.3 months, Table 1) and
was less for patients with metastatic disease compared
with local or extended disease (1.6 months, 95%CI
1.6e1.7; 4.6 months, 95%CI 4.4e4.8; 4.1 months, 95%
CI 4.0e4.3, respectively). In all patients with supportive
care only, the 3-month survival decreased significantly
from 44.6% (95%CI 43.2e46.1) in 1997e2000 to 36.4%
(95%CI 35.2e37.7) in 2013e2016 (Supplemental
Fig. 1C).
4. Discussion
This Dutch population-based study found an increasing
incidence of PDAC in the period 1997e2016 and 23%more patients being treated with resection and/or sys-
temic treatment. The resection rate doubled (8.3%e
16.6%), more patients received adjuvant chemotherapy
(3.0%e56.2%), and 3-year overall survival following
resection increased (16.9%e25.4%). The proportion of
patients with metastatic disease who received palliative
chemotherapy increased (5.3%e16.1%), whereas 1-year
survival improved (13.3%e21.2%). Most strikingly,
however, throughout the entire study period, the ma-
jority of patients received supportive care only. This
could explain the negligible improvement in overall
survival of only 3 weeks (0.7 months) to 3.8 months for
the entire population.
It appears that improvements in oncological treat-
ments of any kind are the most likely explanations for
the increased overall survival. However, the overall
survival advantage for all patients is disappointing
compared with for example colorectal cancer [23]. It is
clear that improvements are needed, for instance
through early detection of PDAC and better or indi-
vidualised treatments [24]. Survival increased in patients
with localised disease who underwent resection in the
most recent years (2009e2016). Resection rates doubled,
Table 3
Univariate and multivariable Cox regressions to assess the effect of resection and chemotherapy on the association between time of diagnosis and
mortality in patients with pancreatic ductal adenocarcinoma (1997e2016).
Cox regression Median overall survival,
months
Multivariable analysis without
treatment variables HR (95 %CI)
Multivariable analysis
including treatment variables
HR (95% CI)
Time of diagnosis
1997e2000 3.1 1.00 (reference) 1.00 (reference)
2001e2004 3.2 0.94 (0.91e0.98) 0.96 (0.93e1.00)
2005e2008 3.5 0.92 (0.89e0.96) 1.00 (0.96e1.03)
2009e2012 3.7 0.82 (0.79e0.85) 0.99 (0.95e1.02)
2013e2016 3.8 0.75 (0.72e0.77) 0.98 (0.95e1.02)
Sex
Male 3.5 1.00 (reference) 1.00 (reference)
Female 3.6 0.98 (0.96e1.00) 0.96 (0.94e0.98)
Age
<60 years 5.2 1.00 (reference) 1.00 (reference)
60e74 years 3.9 1.24 (1.21e1.28) 1.11 (1.08e1.14)
75 years 2.5 1.91 (1.86e1.97) 1.32 (1.27e1.36)
SES
Low 3.8 1.00 (reference) 1.00 (reference)
Medium 3.5 1.03 (1.01e1.06) 1.01 (0.99e1.04)
High 3.3 1.08 (1.06e1.11) 1.05 (1.02e1.08)
Primary tumour location
Head of pancreas 4.3 1.00 (reference) 1.00 (reference)
Body of pancreas 3.2 1.08 (1.04e1.12) 1.06 (1.02e1.10)
Tail of pancreas 2.1 1.19 (1.15e1.23) 1.24 (1.20e1.28)
Other 2.4 1.23 (1.19e1.27) 1.21 (1.17e1.25)
Tumour stagea
Local disease/within pancreas 5.7 1.00 (reference) 1.00 (reference)
Extended disease/growth outside pancreas 7.6 1.09 (1.05e1.13) 1.35 (1.30e1.40)
Metastases 2.2 2.69 (2.59e2.79) 2.53 (2.44e2.63)
Unknown 2.7 1.59 (1.51e1.67) 1.40 (1.33e1.47)
Resection Not included
Yes 16.9 1.00 (reference)
No 2.9 2.54 (2.45e2.64)
Any chemotherapy treatment Not included
Yes 9.1 1.00 (reference)
No 2.6 2.21 (2.14e2.27)
HR, hazard ratio; SES, socioeconomic status; CI, confidence interval; TNM, tumour-node-metastasis.
Bold numbers indicate statistical significance.
a Tumour stage was based on the pathological TNM classification at the time of registration, supplemented with the clinical TNM in case of
non-resected tumours or neoadjuvant therapy
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improved referral patterns, improved surgical
techniques anddin recent yearsdextending indications
for surgery (e.g. locally advanced disease with response
to chemotherapy) [25]. Moreover, postoperative com-
plications and mortality after pancreatic resection
decreased, which increased the number of patients
eligible for adjuvant treatment [26e28]. This increase
was probably also strongly related to several adjuvant
chemotherapy studies, such as the ESPAC-1 trial in
2004 and the CONKO-001 trial in 2007 [2,29]. The use
of neoadjuvant chemo (radio)therapy mainly increased
since 2013 with the start of the Dutch PREOPANC-1
trial on neoadjuvant chemoradiotherapy in patients
with (borderline) resectable pancreatic cancer (NL3525,
EudraCT number 2012-003181-40) [30]. Survival in pa-
tients with localised disease who undergo a resectionmay further improve because of new (neo)adjuvant
chemotherapy regimens, as recently was proven for
adjuvant therapy with modified FOLFIRINOX [31]. In
patients who underwent a resection, the use of radio-
therapy was negligible during the study period. The role
of radiotherapy remains under debate, and literature is
inconclusive [32].
In patients with metastatic disease who received
chemotherapy, survival rates increased, especially from
2005 to 2008 to 2009e2012 (1-year survival 12.7% and
21.2%, respectively), probably explained by the uptake
of new combinations of chemotherapeutic agents
FOLFIRINOX and gemcitabine plus nab-paclitaxel
[3e5]. The percentage of patients who only received
supportive care decreased, as did their survival. More
patients were treated with chemotherapy and relatively
more elderly underwent surgery and thus especially
A.E.J. Latenstein et al. / European Journal of Cancer 125 (2020) 83e93 91patients with a relatively poor prognosis received sup-
portive care only and subsequently overall survival
decreased [33].
Locally advanced pancreatic cancer was initially not
registered in the NCR, and in this study, these patients
were categorised as patients with localised disease
without metastases. Depending on their treatment, they
were included in the group of patients who underwent
resection or patients with localised disease who received
chemo (radio)therapy without resection. This last group
was small but increased over the years, probably related
to more attention for patients with locally advanced
disease after the introduction of FOLFIRINOX [34]. In
addition, after FOLFIRINOX treatment emerged,
resection rates in patients with locally advanced disease
increased [7,8].
Survival differed between tumour locations. Patients
with tumours of the pancreatic body or tail had worse
survival compared with patients with pancreatic head
tumours. This was also seen in other series [35,36].
Diagnostic delay of patients with body and tail tumours,
because of lack of early symptoms such as jaundice, may
play some role, but it seems that body and tail tumours
mostly have a more aggressive tumour biology [37e39].
In general, the incidence of PDAC varies across
countries [11,12,40]. The incidence is highest in North
America and Western Europe and continues to increase
[11,12,41,42]. This increase could be related to the
increased exposure to risk factors, such as obesity,
alcohol or diabetes and because of increased availability
of high-quality cross-sectional imaging [11,12,40]. Better
diagnostic modalities could explain the increased pro-
portion of patients with metastatic disease at diagnosis
(i.e. stage migration). Older age was given a greater
weighting in the RESP, and therefore, the incidence was
higher if calculated with the RESP than with the ESP,
which represents the age shift that is occurring in
Europe. An analysis of incidence of PDAC across
Europe described an age-standardised incidence, based
on the ESP, between 12 (UK/Ireland and southern
Europe) to 15 (northern and eastern Europe) per
100.000 persons per year between 2000 and 2007 [43].
The incidence in our population was lower in this period
with 8e9 per 100.000 person annually.
The findings of this study should be seen in light of
several limitations. First, the division of the patients into
four subgroups based on clinical findings of metastases
and treatment. A classification in the commonly seen
subgroups of resectable, locally advanced, and meta-
static disease was not possible. Second, the actual inci-
dence of PDAC might have been higher than reported in
the NCR [44]. However, this probably did not influence
the trend over the years because the notification sources
of the NCR remained stable, and similar patterns of
mortality rates in Statistics Netherlands were found [45].Third, information on tumour stage was lacking in
several patients diagnosed in earlier time periods. Stage
migration because of improved imaging equipment may
have influenced grouping of patients but not patterns in
the entire population. The main strength of this study is
the analysis of population-based nationwide data with a
very high national coverage. The results are therefore
more representative than studies with selective cohorts,
for example randomised controlled trials or from single,
high volume centres.
In conclusion, the incidence of PDAC increased over
the last two decades, while overall survival only
improved marginally despite an increase of patients
receiving treatment (16%e39%). Survival increased in
the subgroup of patients who underwent pancreatic
resection (3-year survival: 16.9%e25.4%) and in patients
with metastatic disease who received chemotherapy (1-
year survival: 13.3%e21.2%). However, because the
survival of pancreatic cancer only improved with 3
weeks for the entire population and still the majority of
patients only received supportive care, there is a clear
and urgent need for further improvement in diagnostics
and treatment of PDAC.Conflict of interest statement
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